share_log

Wedbush Initiates Coverage On ARS Pharmaceuticals With Outperform Rating, Announces Price Target of $10

Wedbush Initiates Coverage On ARS Pharmaceuticals With Outperform Rating, Announces Price Target of $10

Wedbush 开始报道评级为跑赢大盘的ARS Pharmicals,宣布目标价为10美元
Benzinga Real-time News ·  2023/01/31 07:15

Wedbush analyst Andreas Argyrides initiates coverage on ARS Pharmaceuticals (NASDAQ:SPRY) with a Outperform rating and announces Price Target of $10.

韦德布什分析师Andreas Argyrides以优于大盘的评级启动对ARS制药(纳斯达克:SPRY)的报道,并宣布目标价为10美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发